Kun Qing1, Borna Mehrad1, John P. Mugler, III1, Kai Ruppert1,2, Jaime F. Mata1, Nicholas J. Tustison1, Steven Guan1, Y. Michael Shim1, Iulian C. Ruset3, F. William Hersman3,4, and Talissa A. Altes1,5
1University of Virginia, Charlottesville, VA, United States, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States, 3Xemed LLC, Durham, NH, United States, 4University of New Hampshire, Durham, NH, United States, 5University of Missouri, Columbia, MO, United States
Synopsis
Idiopathic
pulmonary fibrosis (IPF) is a fatal disease leading to 40,000 deaths each year
in the US. Current clinical tools are remarkably limited in their ability to
discriminate between subsets of IPF patients. In this study, we demonstrated the
ability of a recently developed imaging tool, hyperpolarized xenon-129 MRI, to detect
pulmonary physiology highly relevant to pathology found in IPF with 3-D
resolution. Xenon-129 MRI may represent a novel tool that can detect previously
unrecognized subsets of patients with IPF relevant to treatment and prognosis of
this disease.Introduction
Idiopathic pulmonary fibrosis (IPF)
is a progressive disease that culminates in death from respiratory failure a
median of 3 years after diagnosis, and that causes 40,000 deaths each year in
the US [1, 2].
A key challenge in the care of IPF patients is that the natural history of the
illness is unpredictable, with some patients having frequent exacerbations in
quick succession leading to rapid deterioration and death, while others have a
more benign course with few or no exacerbations [3].
Current clinical tools, including chest CT, pulmonary function tests (PFTs),
and lung biopsy are remarkably limited in their ability to discriminate between
subsets of IPF patients and correlate with disease prognosis. Hyperpolarized
xenon-129 (Xe129) MRI is a powerful, recently-developed technology that
provides regional and quantitative information about regional lung ventilation,
gas uptake (exchange) and perfusion [4], but has not been studied in IPF to date.
Purpose
To test the ability of hyperpolarized xenon-129
MRI to detect changes of lung physiology in subjects with IPF.
Methods
Seven patients with IPF (age 66±15)
and 10 age-matched healthy controls (age 58±14) underwent PFTs including spirometry
and diffusion capacity (DLCO), and hyperpolarized xenon-129 MRI including 3-D ventilation
(resolution: 4x4x15 mm
3) and dissolved-phase (Xe129 DP) imaging (resolution
7.6x7.6x17.6 mm
3) [4]. Four
metrics were generated from the Xe129 MRI, including measurement of airflow
obstruction: percent ventilation defects (Vdef%) [5], and three measurements
of gas uptake into lung tissue and blood: tissue-to-gas, RBC-to-gas, and
RBC-to-tissue ratios [4]. Mann-Whitney U test was used to compare the PFT and
MRI data acquired from the IPF and control groups.
Results and Discussion
As compared to controls, patients with IPF had significantly
lower FEV
1 %pred (IPF: 68±19%, control: 112±13%, p<0.001), FVC %pred (IPF:
67±19%, control: 121±29%, p<0.001) and DLCO/Va %pred (IPF: 75±18%, control:
93±14%, p=0.04), but higher FEV
1/FVC (IPF: 0.82±0.04, control: 0.77±0.06,
p=0.026). On xenon-129 MRI, IPF patients had ventilation defects close to those
from controls (IPF: 31±11%, control: 21±9%, p=0.041; Fig. 1, right column). In
contrast, the measured gas exchange from lung parenchyma to blood was
significantly lower in subjects with IPF (RBC-to-tissue ratio: IPF: 0.19±0.05,
control: 0.28±0.05, p=0.002; Fig. 1, middle column). Interestingly, the gas uptake by tissue was
significantly higher in IPF compared to healthy subjects (tissue-to-gas ratio:
IPF: 1.41±0.14%, control: 1.10±0.17%, p=0.005; Fig. 1, left column), a finding
that may be attributable to septal wall thickening due to pulmonary fibrosis or
inflammation. In addition, IPF patients showed marked regional heterogeneity in
the tissue-to-gas ratio maps, with the lower lobes and periphery of the lungs
having higher tissue-to-gas ratios than the upper lobes and central regions (an
example shown in Fig. 2). This is consistent with existing findings that IPF is
a disease of the basal and peripheral lungs that progresses centrally and
toward the lung apices over time [6].
Conclusion
We
have demonstrated the ability of hyperpolarized xenon-129 MRI to detect
pulmonary physiology highly relevant to pathology found in IPF with 3-D
resolution. Hyperpolarized xenon-129 MRI may be able to identify previously
unrecognized subsets of patients with IPF that may be relevant to treatment and
prognosis of this disease.
Acknowledgements
This work was supported
by a Transformative, Collaborative Science Pilot Grant from University of
Virginia School of Medicine and NIH R01 HL109618. References
[1] Flaherty, K.R., et al. Am J Respir Crit Care Med, 2001. 164(9): p. 1722-7.
[2]
Nicholson, A.G., et al. Am J
Respir Crit Care Med, 2000. 162(6): p. 2213-7. [3] Collard, H.R., et al. Am J Respir Crit Care Med, 2007. 176(7): p. 636-43.
[4] Qing,
K., et al. J Magn Reson Imaging, 2014.
39(2): p. 346-59. [5] Tustison NJ, et al. J. Magn. Reson. Imaging, 2011.
34(4): p. 831-841. [6] Travis, W.D., et al. Am J Respir Crit Care Med, 2013. 188(6): p. 733-48.